Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norwegian Nucleoside Analogue Stop Study (Nuc-STOP)
2018-000724-34Phase 4Completed
- Sponsor
- Oslo University Hospital
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenofovir disoproxil fumarate and entecavir in Chronic hepatitis B (CHB) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: HBsAg loss within 3 years after stopping NA therapy. Started May 2018; status: completed.
02
Drugs
tenofovir disoproxil fumarateentecavir
03
Conditions
Chronic hepatitis B (CHB)
Beyond the preview
Go deeper on 2018-000724-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000724-34.